Degree of transparency at issue in House hearing on drug pricing bills

Witnesses, including drug company and PBM representatives, weighed in on how much transparency industry might accept during a House subcommittee hearing on bipartisan legislation on drug prices Tuesday.

The hearing included testimony on competing bills that would require manufacturers to report sharp increases in wholesale acquisition cost to HHS. One, the Fair

Read the full 517 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE